High-impact neuromedicines
for real world care

About Us

We are developing medicines that help people with brain disorders live boldly and reclaim the connection, stability, and joy that these conditions can too often take away.

Learn more

Lead. Live. Boldly.

Brain Neural Network

Who We Are

LB is a neuromedicines company

committed to developing and commercializing high-impact therapies that address the multiple dimensions of underserved brain disorders.

Our Pipeline

Late-stage pipeline designed for broad impact

We are evaluating LB-102 for the treatment of schizophrenia, bipolar depression, the adjunctive treatment of major depressive disorder, as well as other neuropsychiatric disorders.

Explore our pipeline

Our Pipeline

Late-stage pipeline designed for broad impact

We are evaluating LB-102 for the treatment of schizophrenia, bipolar depression, the adjunctive treatment of major depressive disorder, as well as other neuropsychiatric disorders.

LB-102

LB-102’s unique mechanism of action and positive Phase 2 data in schizophrenia, as well as the extensive clinical and real-world experience of amisulpride, collectively establish a strong foundation for continued development in both psychosis and mood disorders.

Psychosis Related Disorders

Schizophrenia (Oral)

Phase 3

Schizophrenia (Long-acting injectable)

Preclinical

Mood Disorders

Bipolar 1 Depression (Oral)

Phase 2

Adjunctive MDD (Oral)

Phase 2 (in planning)

Explore our complete pipeline

Careers at LB

Bold action in service of meaningful impact

Join a purpose driven team bringing new energy to the development of neuromedicines.

Find your next career
Home work at LB

Lead. Live. Boldly.

In the News

There’s more to our story

View all news